Mini-review: The therapeutic role of cannabinoids in neuroHIV

• Published in: Neuroscience letters Vol. 750; p. 135717
• Main Authors: Yadav-Samudrala, Barkha J., Fitting, Sylvia
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 17.04.2021
• Subjects: AIDS Dementia Complex - drug therapy; AIDS Dementia Complex - metabolism; Animals; Antiretroviral therapy; C-C motif chemokine receptor 5 (CCR5); C-X-C motif chemokine receptor 4 (CXCR4); Cannabinoid type 1 receptor; Cannabinoid type 2 receptor; Cannabinoids - metabolism; Cannabinoids - therapeutic use; Cannabis; Endogenous cannabinoid system; Fatty acid amide hydrolase; G-protein coupled receptor (GPCR) GPR18; HIV-associated neurocognitive disorders; Humans; Inflammation; Microglia; MJN110; Monoacylglycerol lipase; Neurodegeneration; neuroHIV; PF3845; Receptor, Cannabinoid, CB2 - metabolism; Synaptodendritic degeneration; Δ9-tetrahydrocannabinol; Cannabinoid type 1 receptor; MJN110; C-C motif chemokine receptor 5 (CCR5); Fatty acid amide hydrolase; Endogenous cannabinoid system; Inflammation; PF3845; C-X-C motif chemokine receptor 4 (CXCR4); neuroHIV; Antiretroviral therapy; Microglia; Cannabis; G-protein coupled receptor (GPCR) GPR18; Monoacylglycerol lipase; Neurodegeneration; Synaptodendritic degeneration; Cannabinoid type 2 receptor; HIV-associated neurocognitive disorders; Δ9-tetrahydrocannabinol; Δ-tetrahydrocannabinol

[Display omitted] •HIV neuropathogenesis alters the endocannabinoid system.•Effects of cannabis on cognition in HIV-1 depend on various factors, i.e. disease progression, amount of cannabis use, cognitive domain assessed.•Cannabinoid type 2 receptors and endocannabinoid catabolic enzymes are promisi...